Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for burosumab

  1. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  2. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.

    Highly specialised technologies guidance
    Last updated
    8 April 2025
    View recommendations

    Sections for HST8

  3. Evidence on the progression of X-linked hypophosphataemia (XLH) over time and the long-term benefits of burosumab would also be valuable.

    X-linked hypophosphataemia (XLH) over time and the long-term benefits of burosumab would also be valuable. Any explanatory notes(if...

    Research recommendation
    Published
    22 March 2019

  4. In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed that further research into the treatment benefit of burosumab in young people aged 13 years and over would relieve some of the clinical uncertainty in an age group covered by the marketing authorisation.

    Recommendation ID HST8/1 Question In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and...

    Research recommendation
    Published
    22 March 2019

  5. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development Reference number: GID-TA10822 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. The committee also noted that the additional evidence exploring the relationship between radiological measures of bone defects (that is, the Rickets Severity Score and the Radiographic Global Impression of Change) and health-related quality of life would help to address several key uncertainties in the economic analysis.

    None Source guidance details Comes from guidance Burosumab for treating X-linked hypophosphataemia in children and young people

    Research recommendation
    Published
    22 March 2019

  7. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

    Highly specialised technologies guidance
    Published
    5 May 2022
    View recommendations

    Sections for HST20